SNOA
Sonoma Pharmaceuticals, Inc.
There isn't enough reported data to score SNOA yet.
SNOA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Weak | |
| Unavailable |
SNOA's revenue is currently strong, and its profitability is stable, but its cash flow is weak. There isn't enough data to rate its balance sheet.
SNOA PE Valuation
SNOA has no meaningful PE right now: it lost money over the past year.
SNOA Forward outlook
There aren't enough analyst estimates for SNOA to show an outlook.
SNOA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.91 | +$2.30 |
| Q2 2026 | -$1.22 | +$2.26 |
| Q1 2026 | -$1.89 | +$2.23 |
| Q4 2021 | -$54.20 | -$33.60 |
| Q3 2021 | -$54.40 | -$25.80 |
| Q2 2021 | -$52.40 | -$4.40 |
| Q1 2021 | -$39.40 | +$0.40 |
SNOA is still losing money, but far less than before: $0.91 per share over the past year, against $54.40 at its worst in late 2021.
SNOA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.2M | +28% |
| Q2 2026 | $6.4M | +60% |
| Q1 2026 | $5.6M | +48% |
| Q4 2025 | $4.3M | +22% |
| Q3 2025 | $5.6M | +57% |
| Q2 2025 | $4M | +18% |
| Q1 2025 | $3.8M | +9.2% |
| Q4 2024 | $3.6M | +14% |
SNOA's revenue has grown year over year for nine quarters in a row: $7M last quarter, up 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4% | +10 points |
| Q2 2026 | -0.6% | +27 points |
| Q1 2026 | -6.3% | +11 points |
| Q4 2025 | -16% | +13 points |
| Q3 2025 | -6% | +18 points |
| Q2 2025 | -27% | +7.3 points |
| Q1 2025 | -17% | +24 points |
| Q4 2024 | -29% | -2 points |
SNOA's operating margin was 4% last quarter, up 10 points from the same quarter a year ago, near the top of its range since 2019.
SNOA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$778K | -$133K |
| Q2 2026 | -$651K | +$1.5M |
| Q1 2026 | -$548K | -$406K |
| Q4 2025 | -$811K | -244% |
| Q3 2025 | -$645K | -297% |
| Q2 2025 | -$2.1M | -$1.2M |
| Q1 2025 | -$142K | -192% |
| Q4 2024 | $563K | +$1.7M |
SNOA has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
SNOA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +1.1M shares |
| 1 year | +199% | +3.3M shares |
| 3 years | +4591% | +4.8M shares |
SNOA has 5M diluted shares, up 199% from a year ago.
SNOA Net Leverage
SNOA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SNOA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 18.2 | Oversold |
SNOA's weekly RSI is 38 (neutral) and its Stochastic is 18 (oversold).
SNOA PE vs Healthcare Sector
SNOA has no meaningful PE right now: it lost money over the past year.
SNOA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.17 | 0% above |
| 20 week MA | $1.23 | 4.9% below |
| 50 week MA | $1.91 | 39% below |
| 100 week MA | $2.60 | 55% below |
| 200 week MA | $6.66 | 82% below |
SNOA is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
SNOA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.2 | $163.6 | +85% |
| 2021 | $163.6 | $97.0 | -41% |
| 2022 | $97.0 | $23.0 | -76% |
| 2023 | $23.0 | $3.61 | -84% |
| 2024 | $3.61 | $2.75 | -24% |
| 2025 | $2.75 | $3.61 | +31% |
| 2026 YTD | $3.61 | $1.17 | -68% |
SNOA has finished lower in four of the last six years. It's down 68% so far in 2026.